Upcoming Webinars

Accelerate drug discovery with AI-AAM: Using AI to discover drugs and improve existing compounds

Traditional drug discovery is time-consuming, and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board. Join FUJIFILM Wako in this webinar to learn more about how AI-AAM (AI-Amino-Acid Mapping), its new proprietary scaffold-hopping method based on AI and chemical simulation techniques, can be used […]

Register now

rAAV Genome sequencing uncovers transgene integrity and packaging impurities

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar will highlight how long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs were evaluated — which is supporting internal research activities at AstraZeneca. Attendees will hear how library preparation, assessed data quality, and generated important rAAV […]

Register now

Where is the opportunity in the therapeutic antibody market?

In this free webinar, you will hear from Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at Cancer Research Institute; Dr Roger Levy, Senior Global Medical Director, GSK Specialty Medicine; Dr Sheila Keating, VP of Immunology at Gigagen; as well as event sponsors Dr Milind Nigam, Leader – Scientific Solutions Consulting at Benchling, and […]

Register now

Higher throughput bioanalytical methods accelerate the development and evaluation of advanced biotherapeutics

Successful development of advanced biotherapeutics relies on extensive characterisation and tight quality control. Characterising binding properties of complex biomolecules is a critical step. Biophysical data combined with functional assays are needed to predict efficacy and potency, optimise drug delivery, assess critical quality attributes, and improve biologics drug design. Traditional approaches have limited use in a complex […]

Register now

Enhancing collaboration between sponsors and contract partners in drug discovery

Most contemporary drug discovery companies (sponsors) outsource some (or all) drug development to external contract partners, eg. Contract Research Organisations (CROs) and/or Contract Development and Manufacturing Organisations (CDMOs). Communication between sponsor and contract organisation is largely done via email and poorly structured Excel reports which is a highly manual, inefficient, and error-prone process. Additionally, sponsors […]

Register now

Webinars on Demand

Covid targets in the crosshairs: Quality and speed from Arctoris’ Ulysses platform

Covid-19 has highlighted the current operational vulnerabilities in pharmaceutical research and in the drug discovery pipeline. Bringing new drugs to the market is still a slow and expensive process, with far too high costs, failure rates and cycle times. With low reproducibility and inefficient processes delaying the path to approval, the pandemic is prompting a […]

Watch on Demand

Enhancing the predictability of preclinical development

Effective preclinical assessment of drug safety and efficacy is essential to help reduce the risk of drug-induced toxicity and late-stage drug attrition. Current preclinical tests for safety depend on in vivo testing in higher-order species to achieve translational accuracy; however, animal models are expensive and do not adequately recapitulate human physiology due to species differences. […]

Watch on Demand

Evaluation of checkpoint inhibitor therapies using an MLR assay

Immune checkpoints are signalling molecules that control the synapse between T cells and antigen presenting cells (APCs). Checkpoint inhibitor therapies target and inhibit the signals that ‘switch off’ T cells, leading to an upregulation of T cell activation and tumour cell killing.  The mixed lymphocyte reaction (MLR) mimics the T cell and APC synapse by […]

Watch on Demand

Putting the dynamics into compound profiling: using kinetic assays to shape early stage drug discovery

In vitro early stage compound profiling often focusses on single timepoint measurements of drug action, for example the affinity of the drug for its target at equilibrium, or the endpoint response in a signalling assay. However, in vivo, drug action occurs within a highly dynamic system. Drug and competing messenger concentrations at the site of […]

Watch On Demand

Quantifying T cell exhaustion: An insight into BiTE antibodies and CAR-T cells

This webinar looks at T cell exhaustion. This is recognised as a major challenge in the development of immuno-oncology therapies. Used to describe the loss of effector function due to chronic antigen exposure, it commonly occurs within the tumour microenvironment. This impairs the T cells’ ability to effectively eradicate cancerous cells. The development of tumour […]

Watch On Demand

The Kinetics of Drug-Receptor Binding: Why it is important and how we can measure it?

The Kinetics of Drug-Receptor Binding: Why it is important and how we can measure it? Sponsored by BMGLabtech & CISBio Optimizing the receptor binding kinetics of new drugs can have significant benefits, ranging from improved duration of action to enhanced efficacy through the insurmountable antagonism of dynamic physiological systems. Despite this, the kinetics of new […]

Watch On Demand

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free